1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,040 | 1,100 | 09:01 | |
| 1,050 | 1,090 | 08:29 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.04. | NANOVIRICIDES, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 16.02. | NANOVIRICIDES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.02. | NanoViricides GAAP EPS of -$0.18 | 1 | Seeking Alpha | ||
| 15.02. | NanoViricides, Inc.: NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon | 920 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / February 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that it has filed its Quarterly... ► Artikel lesen | |
| 14.02. | NANOVIRICIDES, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 01.02. | NanoViricides, Inc.: Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics | 806 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / February 1, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines... ► Artikel lesen | |
| 29.01. | NanoViricides reports positive safety results for COVID drug candidate | 1 | Seeking Alpha | ||
| 29.01. | NanoViricides, Inc.: Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found | 576 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / January 29, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines... ► Artikel lesen | |
| 19.01. | NANOVIRICIDES, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.01. | NanoViricides, Inc. (NNVC) To Unveil Cutting-Edge Antiviral Breakthroughs At Biotech Showcase 2024 | 2 | Benzinga.com | ||
| 04.01. | NanoViricides, Inc.: NanoViricides to Present at the Biotech Showcase in San Fransisco | 748 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / January 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines... ► Artikel lesen | |
| 28.11.23 | NanoViricides, Inc.: The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part, Reports NanoViricides | 911 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / November 28, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines... ► Artikel lesen | |
| 15.11.23 | NanoViricides, Inc.: NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications | 1.064 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / November 15, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal first quarter ending... ► Artikel lesen | |
| 14.11.23 | NanoViricides, Inc.: Broad-Spectrum Antiviral NV-387 in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development | 601 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / November 14, 2023 / NanoViricides, Inc. (AMEX:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology... ► Artikel lesen | |
| 16.10.23 | NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV | 753 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / October 16, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2023... ► Artikel lesen | |
| 12.10.23 | NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET | 670 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / October 12, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), announces that the Company's President, Dr. Anil Diwan, will be presenting a talk in person at... ► Artikel lesen | |
| 21.08.23 | NanoViricides, Inc.: The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides | 1.132 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / August 21, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines... ► Artikel lesen | |
| 11.07.23 | NanoViricides, Inc.: Company's Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides | 925 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / July 11, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines... ► Artikel lesen | |
| 06.07.23 | NanoViricides, Inc.: Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs | 692 | ACCESSWIRE | SHELTON, CO / ACCESSWIRE / July 6, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") reports that the clinical trial of its broad-spectrum antiviral drug NV-CoV-2 is progressing satisfactorily.NanoViricides... ► Artikel lesen | |
| 29.06.23 | NanoViricides, Inc.: NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun | 776 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / June 29, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") reports that clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June 17, 2023... ► Artikel lesen |
Seite:
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 39,100 | 0,00 % | Übernahme-Gerüchte bei BioTech-Aktien: BioNTech, Formycon, Cardiol Therapeutics und Novo Nordisk im Fokus | Der BioTech-Sektor ist im laufenden Jahr hinter der Performance von Künstlicher Intelligenz und Hightech deutlich zurückbleiben. Das liegt an der hohen Teuerung, die ihrerseits eine baldige Zinssenkung... ► Artikel lesen | |
| KOPIN | 0,811 | +1,25 % | Kopin Says Jury Awards Damages Of About $24.8 Mln To BlueRadios | WASHINGTON (dpa-AFX) - Kopin Corp., Inc. (KOPN) announced Tuesday that a jury verdict was entered on Monday in the U.S. District Court for the District of Colorado finding for the plaintiff... ► Artikel lesen | |
| ONTO INNOVATION | 168,00 | +1,20 % | Onto Innovation (ONTO) Adds New Capability to Dragonfly System | ||
| FENDX TECHNOLOGIES | 0,207 | 0,00 % | FendX optimiert seine REPELWRAP-Folie durch zusätzliche Produktionstestläufe auf der kommerziellen Fertigungslinie von Dunmore und informiert über Neuigkeiten aus dem Unternehmen | OAKVILLE, Ontario - 23. April 2024 / IRW-Press / - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF)
(FWB: E8D) (das "Unternehmen" oder
"FendX"), ein Nanotechnologieunternehmen, das Oberflächenschutzbeschichtungen... ► Artikel lesen | |
| ACACIA RESEARCH | 4,520 | 0,00 % | Acacia Research Reports Fourth Quarter 2023 Financial Results | NEW YORK--(BUSINESS WIRE)--Acacia Research Corporation (Nasdaq: ACTG) ("Acacia" or the "Company") today reported financial results for the three months and full year ended December 31, 2023.
Martin... ► Artikel lesen | |
| ADVANCE ZINCTEK | 0,505 | -1,94 % | ADVANCE ZINCTEK LIMITED: US Sales | ||
| LEHNER INVESTMENTS | 0,034 | +6,25 % | EQS-News: LEHNER INVESTMENTS AG - Neuer Vorstand, Wechsel im Aufsichtsrat | EQS-News: LEHNER INVESTMENTS AG
/ Schlagwort(e): Personalie
LEHNER INVESTMENTS AG - Neuer Vorstand, Wechsel im Aufsichtsrat
24.04.2024 / 11:24 CET/CEST
Für den Inhalt... ► Artikel lesen | |
| NANOFOCUS | 0,200 | 0,00 % | Nanofocus: Investor verlängert die Frist | Die Carl Mahr Holding hat im März ein freiwilliges öffentliches Erwerbsangebot für die Aktien von Nanofocus abgegeben. Geboten werden dabei 0,50 Euro je Aktie von Nanofocus. Ursprünglich konnten Investoren... ► Artikel lesen | |
| RIBER | 2,730 | +1,49 % | RIBER: Strong growth in 2023 full-year earnings | Strong growth in 2023 full-year earnings Revenues: €39.3m (+41%) driven by the robust development of systems (+96%)Operating income: €3.9m, representing 10% of revenuesNet income: €3.4m, representing... ► Artikel lesen | |
| DOTZ NANO | 0,066 | 0,00 % | DOTZ NANO LIMITED: Change of Auditor | ||
| ZENTEK | 1,060 | +3,92 % | Zentek Ltd.: Zentek Announces U.S. Distribution Agreement for ZenGUARDTM-Enhanced Surgical Masks with Medwell Solutions | GUELPH, ON / ACCESSWIRE / April 3, 2024 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN), an intellectual property development and commercialization company, is pleased to announce... ► Artikel lesen | |
| GOMSPACE | 0,342 | 0,00 % | GomSpace A/S: GomSpace receives order for cutting-edge products from diverse customers at a total value of €923.000 (approx. 10.8MSEK) | STOCKHOLM, Oct. 31, 2023 /PRNewswire/ -- GomSpace gives an update on its product business and announces that the company has received, since the last press release on September 21, new product... ► Artikel lesen | |
| REGION GROUP | 1,298 | 0,00 % | REGION GROUP: Change in substantial holding | ||
| XTPL | 31,800 | -5,07 % | EQS-News: XTPL S.A.: XTPL liefert weiteres Industriemodul an HB Technology | Emittent / Herausgeber: XTPL S.A.
/ Schlagwort(e): Vereinbarung
XTPL liefert weiteres Industriemodul an HB Technology
18.04.2024 / 09:15 CET/CEST
Für den Inhalt der... ► Artikel lesen | |
| NANOFORM FINLAND | 2,580 | 0,00 % | Nanoform successfully completes new share issue raising EUR 15.4 million to invest in commercialization of nanoparticle enabled formulations for next generation medicines |
NANOVIRICIDES INC gehört der Branche Nanotechnologie an. Die relative Kursveränderung beträgt aktuell -0,95 % bei einem Aktienkurs von 1,040 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
